nodes	percent_of_prediction	percent_of_DWPC	metapath
Vildagliptin—DPP4—exocrine gland—esophageal cancer	0.146	0.259	CbGeAlD
Vildagliptin—DPP9—lung—esophageal cancer	0.105	0.187	CbGeAlD
Vildagliptin—DPP9—lymph node—esophageal cancer	0.0721	0.128	CbGeAlD
Vildagliptin—DPP4—epithelium—esophageal cancer	0.0634	0.112	CbGeAlD
Vildagliptin—DPP4—smooth muscle tissue—esophageal cancer	0.0611	0.108	CbGeAlD
Vildagliptin—DPP4—digestive system—esophageal cancer	0.0482	0.0856	CbGeAlD
Vildagliptin—DPP4—lung—esophageal cancer	0.0403	0.0715	CbGeAlD
Vildagliptin—Localized exfoliation—Capecitabine—esophageal cancer	0.0383	0.0878	CcSEcCtD
Vildagliptin—DPP4—lymph node—esophageal cancer	0.0276	0.0489	CbGeAlD
Vildagliptin—Infection—Carboplatin—esophageal cancer	0.0169	0.0388	CcSEcCtD
Vildagliptin—Blister—Capecitabine—esophageal cancer	0.0143	0.0328	CcSEcCtD
Vildagliptin—Skin exfoliation—Cisplatin—esophageal cancer	0.0134	0.0306	CcSEcCtD
Vildagliptin—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.0114	0.0262	CcSEcCtD
Vildagliptin—Skin exfoliation—Capecitabine—esophageal cancer	0.00985	0.0226	CcSEcCtD
Vildagliptin—Nasopharyngitis—Cisplatin—esophageal cancer	0.00908	0.0208	CcSEcCtD
Vildagliptin—Pancreatitis—Cisplatin—esophageal cancer	0.00861	0.0197	CcSEcCtD
Vildagliptin—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00857	0.0196	CcSEcCtD
Vildagliptin—Dermatitis bullous—Capecitabine—esophageal cancer	0.00783	0.018	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Cisplatin—esophageal cancer	0.0074	0.017	CcSEcCtD
Vildagliptin—Skin exfoliation—Methotrexate—esophageal cancer	0.00733	0.0168	CcSEcCtD
Vildagliptin—Liver function test abnormal—Capecitabine—esophageal cancer	0.00691	0.0158	CcSEcCtD
Vildagliptin—Connective tissue disorder—Cisplatin—esophageal cancer	0.00691	0.0158	CcSEcCtD
Vildagliptin—Nasopharyngitis—Capecitabine—esophageal cancer	0.0067	0.0153	CcSEcCtD
Vildagliptin—Malnutrition—Cisplatin—esophageal cancer	0.00612	0.014	CcSEcCtD
Vildagliptin—Flatulence—Cisplatin—esophageal cancer	0.00603	0.0138	CcSEcCtD
Vildagliptin—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00601	0.0138	CcSEcCtD
Vildagliptin—Weight increased—Capecitabine—esophageal cancer	0.00589	0.0135	CcSEcCtD
Vildagliptin—Infestation NOS—Capecitabine—esophageal cancer	0.00577	0.0132	CcSEcCtD
Vildagliptin—Infestation—Capecitabine—esophageal cancer	0.00577	0.0132	CcSEcCtD
Vildagliptin—Tremor—Cisplatin—esophageal cancer	0.00573	0.0131	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00546	0.0125	CcSEcCtD
Vildagliptin—Hepatitis—Capecitabine—esophageal cancer	0.00518	0.0119	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00517	0.0119	CcSEcCtD
Vildagliptin—Liver function test abnormal—Methotrexate—esophageal cancer	0.00515	0.0118	CcSEcCtD
Vildagliptin—Oedema peripheral—Capecitabine—esophageal cancer	0.0051	0.0117	CcSEcCtD
Vildagliptin—Connective tissue disorder—Capecitabine—esophageal cancer	0.00509	0.0117	CcSEcCtD
Vildagliptin—Oedema—Cisplatin—esophageal cancer	0.00499	0.0114	CcSEcCtD
Vildagliptin—Infection—Cisplatin—esophageal cancer	0.00496	0.0114	CcSEcCtD
Vildagliptin—Nervous system disorder—Cisplatin—esophageal cancer	0.0049	0.0112	CcSEcCtD
Vildagliptin—Skin disorder—Cisplatin—esophageal cancer	0.00485	0.0111	CcSEcCtD
Vildagliptin—Hyperhidrosis—Cisplatin—esophageal cancer	0.00483	0.0111	CcSEcCtD
Vildagliptin—Pancreatitis—Methotrexate—esophageal cancer	0.00472	0.0108	CcSEcCtD
Vildagliptin—Angiopathy—Capecitabine—esophageal cancer	0.0047	0.0108	CcSEcCtD
Vildagliptin—Chills—Capecitabine—esophageal cancer	0.00465	0.0107	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00455	0.0104	CcSEcCtD
Vildagliptin—Malnutrition—Capecitabine—esophageal cancer	0.00451	0.0103	CcSEcCtD
Vildagliptin—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00448	0.0103	CcSEcCtD
Vildagliptin—Flatulence—Capecitabine—esophageal cancer	0.00444	0.0102	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00431	0.00988	CcSEcCtD
Vildagliptin—Infestation—Methotrexate—esophageal cancer	0.0043	0.00985	CcSEcCtD
Vildagliptin—Infestation NOS—Methotrexate—esophageal cancer	0.0043	0.00985	CcSEcCtD
Vildagliptin—Tremor—Capecitabine—esophageal cancer	0.00422	0.00968	CcSEcCtD
Vildagliptin—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00406	0.00931	CcSEcCtD
Vildagliptin—Hepatitis—Methotrexate—esophageal cancer	0.00386	0.00884	CcSEcCtD
Vildagliptin—Arthralgia—Capecitabine—esophageal cancer	0.00384	0.0088	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00381	0.00874	CcSEcCtD
Vildagliptin—Oedema—Capecitabine—esophageal cancer	0.00368	0.00844	CcSEcCtD
Vildagliptin—Infection—Capecitabine—esophageal cancer	0.00366	0.00838	CcSEcCtD
Vildagliptin—Nervous system disorder—Capecitabine—esophageal cancer	0.00361	0.00827	CcSEcCtD
Vildagliptin—Asthenia—Cisplatin—esophageal cancer	0.00358	0.00821	CcSEcCtD
Vildagliptin—Skin disorder—Capecitabine—esophageal cancer	0.00357	0.00819	CcSEcCtD
Vildagliptin—Hyperhidrosis—Capecitabine—esophageal cancer	0.00356	0.00815	CcSEcCtD
Vildagliptin—Angiopathy—Methotrexate—esophageal cancer	0.0035	0.00802	CcSEcCtD
Vildagliptin—Chills—Methotrexate—esophageal cancer	0.00346	0.00793	CcSEcCtD
Vildagliptin—Diarrhoea—Cisplatin—esophageal cancer	0.00342	0.00783	CcSEcCtD
Vildagliptin—Malnutrition—Methotrexate—esophageal cancer	0.00336	0.00769	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00335	0.00769	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00318	0.00728	CcSEcCtD
Vildagliptin—Fatigue—Capecitabine—esophageal cancer	0.00317	0.00727	CcSEcCtD
Vildagliptin—Constipation—Capecitabine—esophageal cancer	0.00315	0.00721	CcSEcCtD
Vildagliptin—Nausea—Cisplatin—esophageal cancer	0.00297	0.0068	CcSEcCtD
Vildagliptin—Urticaria—Capecitabine—esophageal cancer	0.00292	0.0067	CcSEcCtD
Vildagliptin—Arthralgia—Methotrexate—esophageal cancer	0.00286	0.00655	CcSEcCtD
Vildagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00284	0.00651	CcSEcCtD
Vildagliptin—Infection—Methotrexate—esophageal cancer	0.00272	0.00624	CcSEcCtD
Vildagliptin—Nervous system disorder—Methotrexate—esophageal cancer	0.00269	0.00616	CcSEcCtD
Vildagliptin—Skin disorder—Methotrexate—esophageal cancer	0.00266	0.0061	CcSEcCtD
Vildagliptin—Hyperhidrosis—Methotrexate—esophageal cancer	0.00265	0.00607	CcSEcCtD
Vildagliptin—Asthenia—Capecitabine—esophageal cancer	0.00264	0.00605	CcSEcCtD
Vildagliptin—Diarrhoea—Capecitabine—esophageal cancer	0.00252	0.00577	CcSEcCtD
Vildagliptin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.0025	0.00572	CcSEcCtD
Vildagliptin—Dizziness—Capecitabine—esophageal cancer	0.00243	0.00558	CcSEcCtD
Vildagliptin—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00237	0.00542	CcSEcCtD
Vildagliptin—Fatigue—Methotrexate—esophageal cancer	0.00236	0.00541	CcSEcCtD
Vildagliptin—Headache—Capecitabine—esophageal cancer	0.00231	0.00528	CcSEcCtD
Vildagliptin—Nausea—Capecitabine—esophageal cancer	0.00219	0.00501	CcSEcCtD
Vildagliptin—Urticaria—Methotrexate—esophageal cancer	0.00218	0.00499	CcSEcCtD
Vildagliptin—Asthenia—Methotrexate—esophageal cancer	0.00197	0.00451	CcSEcCtD
Vildagliptin—Diarrhoea—Methotrexate—esophageal cancer	0.00187	0.0043	CcSEcCtD
Vildagliptin—Dizziness—Methotrexate—esophageal cancer	0.00181	0.00415	CcSEcCtD
Vildagliptin—Headache—Methotrexate—esophageal cancer	0.00172	0.00393	CcSEcCtD
Vildagliptin—Nausea—Methotrexate—esophageal cancer	0.00163	0.00373	CcSEcCtD
